CRISPR Therapeutics is forecast to grow earnings and revenue by 69.7% and 70.1% per annum respectively. EPS is expected to grow by 69.1% per annum. Return on equity is forecast to be -16.6% in 3 years.
Key information
69.7%
Earnings growth rate
69.14%
EPS growth rate
Biotechs earnings growth
24.1%
Revenue growth rate
70.1%
Future return on equity
-16.60%
Analyst coverage
Good
Last updated
05 Aug 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
DB:1CG - Analysts future estimates and past financials data (USD Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
665
-111
-165
249
9
12/31/2027
179
-353
-260
-208
14
12/31/2026
54
-438
-450
124
12
6/30/2026
13
-451
-374
-370
N/A
3/31/2026
4
-569
-426
-400
N/A
12/31/2025
4
-582
-371
-345
N/A
9/30/2025
38
-488
-328
-302
N/A
6/30/2025
38
-468
-351
-325
N/A
3/31/2025
38
-386
-308
-306
N/A
12/31/2024
37
-366
-145
-143
N/A
9/30/2024
203
-240
-191
-189
N/A
6/30/2024
202
-266
-127
-122
N/A
3/31/2024
272
-217
-169
-159
N/A
12/31/2023
371
-154
-272
-260
N/A
9/30/2023
170
-354
-295
-278
N/A
6/30/2023
170
-416
-363
-343
N/A
3/31/2023
100
-524
-377
-352
N/A
12/31/2022
1
-650
-533
-496
N/A
9/30/2022
14
-681
-509
-468
N/A
6/30/2022
15
-633
-516
-445
N/A
3/31/2022
915
312
414
504
N/A
12/31/2021
915
378
457
539
N/A
9/30/2021
902
412
465
544
N/A
6/30/2021
902
447
502
549
N/A
3/31/2021
1
-392
-309
-287
N/A
12/31/2020
1
-349
-257
-238
N/A
9/30/2020
77
-211
-167
-154
N/A
6/30/2020
289
20
45
55
N/A
3/31/2020
289
46
N/A
48
N/A
12/31/2019
290
67
N/A
57
N/A
9/30/2019
213
-11
N/A
25
N/A
6/30/2019
1
-200
N/A
-128
N/A
3/31/2019
2
-185
N/A
-117
N/A
12/31/2018
3
-165
N/A
-96
N/A
9/30/2018
35
-117
N/A
-83
N/A
6/30/2018
37
-91
N/A
-79
N/A
3/31/2018
40
-75
N/A
-69
N/A
12/31/2017
41
-68
N/A
-70
N/A
9/30/2017
11
-51
N/A
-75
N/A
6/30/2017
10
-41
N/A
-71
N/A
3/31/2017
7
-36
N/A
-69
N/A
12/31/2016
5
-23
N/A
-53
N/A
9/30/2016
3
-53
N/A
33
N/A
6/30/2016
2
-44
N/A
40
N/A
3/31/2016
1
-31
N/A
51
N/A
12/31/2015
0
-26
N/A
59
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1CG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: 1CG is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 1CG is expected to become profitable in the next 3 years.
Revenue vs Market: 1CG's revenue (70.1% per year) is forecast to grow faster than the German market (6.6% per year).
High Growth Revenue: 1CG's revenue (70.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1CG is forecast to be unprofitable in 3 years.
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/05 00:00
End of Day Share Price
2026/08/05 00:00
Earnings
2026/06/30
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CRISPR Therapeutics AG is covered by 40 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.